Analysis Shows Credo’s VitaPCR™ SARS-CoV-2 Related Assays are capable of detecting the new variant strain Omicron Variant correctly
In response to the new variant strain Omicron variant ( […]
In response to the new variant strain Omicron variant ( […]
Focusing on research and development of revolutionary diagnostic technologies since 2011, Credo Diagnostics develops, manufactures, and commercializes accurate, rapid, and affordable molecular diagnostic solutions at the Point-Of-Care testing.
© 2023 | Credo Diagnostics Biomedical Pte. Ltd.
